Get the Stockscreener App
0.224
1.82%
0.004
Abpro Holdings Inc stock is traded at $0.224, with a volume of 315.65K.
It is up +1.82% in the last 24 hours and down -2.61% over the past month.
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.
See More
Previous Close:
$0.22
Open:
$0.2225
24h Volume:
315.65K
Relative Volume:
0.03
Market Cap:
$16.59M
Revenue:
-
Net Income/Loss:
$-8.09M
P/E Ratio:
-1.3844
EPS:
-0.1618
Net Cash Flow:
$-8.31M
1W Performance:
-11.85%
1M Performance:
-2.61%
6M Performance:
-79.64%
1Y Performance:
+0.00%
1-Day Range:
$0.21
$0.226
1-Week Range:
$0.20
$0.25
52-Week Range:
$0.1516
$5.13
Abpro Holdings Inc Stock (ABP) Company Profile
Name
Abpro Holdings Inc
Sector
Industry
Phone
248-890-7200
Address
6 ST JOHNS LANE, FLOOR 5, NEW YORK
Compare ABP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABP
Abpro Holdings Inc
|
0.224 | 16.59M | 0 | -8.09M | -8.31M | -0.1618 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.23 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
516.79 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.87 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.40 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
256.12 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Abpro Holdings Inc Stock (ABP) Latest News
Abpro Holdings Postpones Annual Stockholders Meeting - TipRanks
Market Momentum: Abpro Holdings Inc (ABP) Registers a 3.72 Increase, Closing at 0.22 - DWinneX
Abpro Holdings Inc Still Hasn’t Convinced Analysts? - Stocksregister
Nasdaq Top 5 Premarket Gainers: Clik Holdings, Graphjet Technology, NuCana, Ekso Bionics Holdings, Abpro Holdings - MSN
Why Novavax Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Boot Barn Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Everus Construction Group Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Financial Fitness Check: Examining Abpro Holdings Inc (ABP)’s Key Ratios - DWinneX
Abpro Holdings CEO Suk Jin Wook buys shares worth $1,081 By Investing.com - Investing.com India
Abpro Holdings CEO Suk Jin Wook buys shares worth $1,081 - Investing.com Australia
ABP stock plunges to 52-week low, touches $0.23 - Investing.com
Holdings of Abpro Holdings Inc (ABP) are aligned with the stars - Sete News
Closing Strong: Abpro Holdings Inc (ABP) Ends at 0.26, Down -0.27 from Last Close - DWinneX
Abpro Holdings Inc’s latest rating changes from various analysts - knoxdaily.com
Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing - ADVFN
ABP’s Stock Journey: What Investors Need to Know About Abpro Holdings Inc’s Performance - investchronicle.com
Analyzing ABP’s price-to-book ratio for the last quarter - uspostnews.com
Abpro Holdings Presents Promising Preclinical Cancer Data - TipRanks
Why Amplify Energy Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager - The Manila Times
Abpro and Celltrion Reveal Promising Preclinical Data for Bispecific T-Cell Engager ABP-102/CT-P72 Targeting HER2-Positive Cancers - Nasdaq
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing - Bluefield Daily Telegraph
Cancer Drug Shows 2X Better Tumor Suppression in Breakthrough Study | ABP Stock News - Stock Titan
Abpro Holdings CEO Acquires Additional Shares - TradingView
Stocks in play: A&W Food Services of Canada Inc - The Globe and Mail
Abpro Holdings amends convertible note terms with Yorkville - Investing.com
ABP stock plunges to 52-week low, touches $0.23 By Investing.com - Investing.com South Africa
Abpro Holdings identifies errors, to restate prior financials By Investing.com - Investing.com South Africa
Abpro Holdings identifies errors, to restate prior financials - Investing.com Australia
Abpro Holdings, Inc. SEC 10-K Report - TradingView
Abpro Holdings approves significant stock issuance to Yorkville - Investing.com Australia
Abpro Holdings approves significant stock issuance to Yorkville By Investing.com - Investing.com South Africa
Abpro Holdings faces Nasdaq delisting over share price By Investing.com - Investing.com South Africa
Abpro Holdings faces Nasdaq delisting over share price - Investing.com
Abpro Holdings Delays Year-End Financial Report - TipRanks
Abpro Holdings to Present Preclinical Data at AACR 2025 - TipRanks
Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025 - The Manila Times
Groundbreaking Cancer Treatment Data: Abpro's HER2 Therapy Selected for Major AACR Showcase - Stock Titan
Abpro Chief Executive Ian Chan Departs -March 11, 2025 at 04:42 am EDT - Marketscreener.com
Abpro Statement on the Departure of Former CEO Ian Chan - The Manila Times
Abpro Advances Potential Best-in-Class HER2 Cancer Treatment Amid Leadership Change - Stock Titan
Abpro Holdings Inc Stock (ABP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Abpro Holdings Inc Stock (ABP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Suk Jin Wook (Miles) | CEO and Chairman |
Apr 29 '25 |
Buy |
0.25 |
4,325 |
1,081 |
130,277 |
| Suk Jin Wook (Miles) | CEO and Chairman |
Apr 24 '25 |
Buy |
0.34 |
26,542 |
9,024 |
125,902 |
| Suk Jin Wook (Miles) | CEO and Chairman |
Apr 23 '25 |
Buy |
0.28 |
7,460 |
2,089 |
99,360 |
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):